If you have been reading about somatotroph and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-11-03. Where a claim depends on a specific study, the study is described rather than over-claimed.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
| Property | Value | Notes |
|---|---|---|
| Target receptor | GHRH receptor (GHRHR) | Expressed on pituitary somatotrophs |
| Primary action | Stimulates growth hormone release | Amplifies pulse size |
| Half-life, albumin-binding form | Several days as reported | Slow release from albumin complex |
| Half-life, unmodified analog | About 30 minutes in animal estimates | Cleared by proteases and filtration |
| Common analytical approach | LC-MS/MS for peptide, immunoassay for hormones | Methods answer different questions |
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
==== Immune suppressants ==== The steroid prednisone might also be used to achieve a better result, but it can lead to the worsening of symptoms and takes weeks to achieve its maximal effectiveness. Research suggests that up to 15% of people with myasthenia gravis do not positively respond to immune suppressants. Due to the myriad symptoms that steroid treatments can cause, it is not the preferred method of treatment. Other immune suppressing medications may also be used including rituximab,azathioprine and especially mycophenolate. Nipocalimab (Imaavy) was approved for medical use in the United States in April 2025.
1993/29) Income Support (General) Amendment Regulations 1993 (S.I. 1993/30) Motor Vehicles (Wearing of Seat Belts by Children in Front Seats) Regulations 1993 (S.I. 1993/31) Food Protection (Emergency Prohibitions) (Radioactivity in Sheep) (Wales) (Partial Revocation) Order 1993 (S.I. 1993/32) Food Protection (Emergency Prohibitions) (Radioactivity in Sheep) (England) (Partial Revocation) Order 1993 (S.I. 1993/33) North West London Mental Health National Health Service Trust (Establishment) Order 1993 (S.I. 1993/34) Road Traffic Regulation Act 1984 (Amendment) Order 1993 (S.I. 1993/35) Local Authorities (Discretionary Expenditure) (Relevant Population) Regulations 1993 (S.I. 1993/40) Local Authorities (Discretionary Expenditure Limits) Order 1993 (S.I. 1993/41) Control of Pollution (Anglers' Lead Weights) (Amendment) Regulations 1993 (S.I. 1993/49) Gipsy Encampments (London Borough of Bromley) Order 1993 (S.I. 1993/50) Licensed Betting Offices (Amendment) Regulations 1993 (S.I. 1993/51) Combined Probation Areas (Powys) Order 1993 (S.I. 1993/52) National Rivers Authority (Anglian Region) (Reconstitution of the Alford Drainage Board) Order 1992 S.I. 1993/53) National Rivers Authority (Anglian Region) (Reconstruction of the North East Lindsey Internal Drainage Board) Order 1992 S.I. 1993/54) National Rivers Authority (Anglian Region) (Reconstitution of the Louth Drainage Board) Order 1992 S.I. 1993/55) Education (Higher Education Corporations) (Wales) (No. 3) Order 1993 (S.I. 1993/56) Friendly Societies (Group Schemes) Regulations 1993 (S.I.
Observations in vitro and of tumours extracted from those five patients suggest that DCA might act against cancer cells by depolarising abnormal mitochondria found in glioblastoma cancer cells – allowing the mitochondria to induce apoptosis (cell death) of the malignant cells. In vitro work with DCA on neuroblastomas (which have fewer recognised mitochondrial abnormalities) showed activity against malignant, undifferentiated cells. A 2016 case report discussed and reviewed the application of DCA in central nervous system malignancies. A 2018 study found that DCA could trigger a metabolic switch from glycolysis (the Warburg effect) to mitochondrial OXPHOS and increase reactive oxygen stress affecting tumor cells. These effects were not observed in non-tumor cells. Current research has focused mainly on combining DCA with other cancer drugs to form prodrug complexes which can release both agents in a more targeted manner.
During 2012, approximately 5.9 metric tons of illicit amphetamine were seized within EU member states; the "street price" of illicit amphetamine within the EU ranged from €6–38 per gram during the same period. Outside Europe, the illicit market for amphetamine is much smaller than the market for methamphetamine and MDMA.
Sources: en.wikipedia.org
== External links == Histology image: 00801ooa – Histology Learning System at Boston University - "Connective Tissue elastic fibers " UIUC Histology Subject 328 Anatomy photo: TermsCells&Tissues/connective/elastic/elastic2 - Comparative Organology at University of California, Davis - "Connective tissue, elastic (LM, High)"
== History == Before SHG was used for imaging, the first demonstration of SHG was performed in 1961 by P. A. Franken, G. Weinreich, C. W. Peters, and A. E. Hill at the University of Michigan, Ann Arbor using a quartz sample. In 1968, SHG from interfaces was discovered by Bloembergen and has since been used as a tool for characterizing surfaces and probing interface dynamics. In 1971, Fine and Hansen reported the first observation of SHG from biological tissue samples. In 1974, Robert W. Hellwarth and Christensen first reported the integration of SHG and microscopy by imaging SHG signals from polycrystalline ZnSe. In 1977, Colin Sheppard imaged various SHG crystals with a scanning optical microscope. The first biological imaging experiments were done by Freund and Deutsch in 1986 to study the orientation of collagen fibers in rat tail tendon. In 1993, Lewis examined the second-harmonic response of styryl dyes in electric fields. He also showed work on imaging live cells. In 2006, Goro Mizutani group developed a non-scanning SHG microscope that significantly shortens the time required for observation of large samples, even if the two-photons wide-field microscope was published in 1996 and could have been used to detect SHG. The non-scanning SHG microscope was used for observation of plant starch, megamolecule, spider silk and so on. In 2010 SHG was extended to whole-animal in vivo imaging. In 2019, SHG applications widened when it was applied to the use of selectively imaging agrochemicals directly on leaf surfaces to provide a way to evaluate the effectiveness of pesticides.
=== Bulk metal preparation === In order to characterize chemical and physical properties of solid berkelium and its compounds, a program was initiated in 1952 at the Material Testing Reactor, Arco, Idaho, US. It resulted in preparation of an eight-gram plutonium-239 target and in the first production of macroscopic quantities (0.6 micrograms) of berkelium by Burris B. Cunningham and Stanley Gerald Thompson in 1958, after a continuous reactor irradiation of this target for six years. This irradiation method was and still is the only way of producing weighable amounts of the element, and most solid-state studies of berkelium have been conducted on microgram or submicrogram-sized samples. The world's major irradiation sources are the 85-megawatt High Flux Isotope Reactor at the Oak Ridge National Laboratory in Tennessee, USA, and the SM-2 loop reactor at the Research Institute of Atomic Reactors (NIIAR) in Dimitrovgrad, Russia, which are both dedicated to the production of transcurium elements (atomic number greater than 96). These facilities have similar power and flux levels, and are expected to have comparable production capacities for transcurium elements, although the quantities produced at NIIAR are not publicly reported. In a "typical processing campaign" at Oak Ridge, tens of grams of curium are irradiated to produce decigram quantities of californium, milligram quantities of berkelium-249 and einsteinium, and picogram quantities of fermium. In total, just over one gram of berkelium-249 has been produced at Oak Ridge since 1967.
In the event wealthy landowners, members of the nascent agrarian bourgeoisie in search of social status, bought the best land. Ferdinand's reforms ended shortly after the French Revolution. Revolutionary ideas were spreading across continental Europe thanks to the invasion of French revolutionary armies, alarming the courts of the Old Regime. Ferdinand IV in 1supported joined the anti-French coalition and marched with his army to Rome, where Pope Pius VI had been deposed and the Roman Republic proclaimed. The Bourbon army had to retreat after initial successes, pursued by French troops supporting the Italian Jacobin revolutionaries. It moved from Naples to Sicily, while on 21 January 1799, the Parthenopean Republic was proclaimed. Its formation document was drafted by the Calabrian Jacobin Giuseppe Logoteta.
=== Tenerife === Upon landing on Tenerife, Humboldt and Bonpland were received by local officials and noted the distinctive flora of the island, including bananas, papaws, and ornamental plants. On June 20, before dawn,Bonpland an Humboldt departed with guides and mules for La Orotava, near the Teide volcano. They passed through San Cristébal, built on a basalt ridge around the Peak of Tenerife, and paused to inspect rocks, eventually arriving at La Laguna, the capital of Tenerife. After the climbing Humboldt and his party left La Laguna, traversing a landscape rich in plant diversity, including palms, orange trees, vines, and cacti. The region’s natural beauty was contrasted by socio-economic inequality, with land concentrated among a few wealthy planters and the indigenous population living in poverty. The group passed through Juan de la Rambla, Victoria, and Matanza, sites of both agricultural abundance and historical conflict with Spanish conquest in the fifteenth century. In La Orotava, they visited the botanical garden and met Monsieur LeGros, the French vice-consul, who had lived on Tenerife since being shipwrecked and agreed to guide their ascent of Pico del Teide. On 21 June 1799, the climbing party, which included LeGros, other local guides, and consular staff, departed for the volcano. The route passed solidly built but somber towns, lush gardens, and a renowned dragon tree, a species present in the Canaries but native to the West Indies, illustrating the complexities of plant distribution.
Sources: en.wikipedia.org
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.
Typical endpoints include growth hormone pulse frequency and amplitude, together with insulin-like growth factor 1 concentration. Some protocols add body composition or metabolic markers. Interpretation depends on baseline hormonal status, which varies widely between individuals.
Most human data come from small, early-stage studies, and independent replication is limited. Short-term effects on growth hormone release are documented; longer-term outcomes are not well characterized. Open questions include changes in pituitary responsiveness after repeated exposure.
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.